CGTX
Cognition Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.70
close · 2026-10-30
value
19
cheaper than peers19
quality
45
stronger fundamentals45
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.01× | 58 |
| cash flow yield, 2 years ago | -24.3% | 41 |
| earnings yield, latest year | -45.8% | 34 |
| earnings yield, 3 years ago | -130.3% | 34 |
| cash flow yield, 3 years ago | -28.2% | 33 |
| cash flow yield, latest year | -37.0% | 32 |
| earnings yield, 2 years ago | -123.2% | 28 |
| cash flow yield, 1 year ago | -42.9% | 28 |
| earnings yield, 1 year ago | -123.2% | 17 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.8% | 59 |
| operating margin | 0.0% | 50 |
| return on equity | -83.8% | 34 |
3 of 4 measures available
Facts
| market cap | $66M |
| free cash flow | -$24.0M |
| employees | 14 |
| first trade | 2021-10-08 |
| next earnings | not reported |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.32 | -0.86 | -0.86 | -0.91 |
| free cash flow | -$24.6M | -$28.5M | -$16.2M | -$18.7M |
| net income | -$23.5M | -$34.0M | -$25.8M | -$21.4M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $0 | -$195,000 | $0 | $0 |